Use of Cannabinoids for the Treatment of OSA

Purpose of ReviewObstructive sleep apnea (OSA) is associated with increased risk of morbidity and mortality. Positive airway pressure (PAP) therapy remains the gold standard treatment, but its use is often limited by patient compliance, hence the need to consider other potential therapies. Preliminary data may suggest potential role of cannabinoids in the treatment of OSA. We aim to summarize the current knowledge on cannabinoid use and its impact on the pathophysiology of OSA as well as its role as a potential management option.Recent FindingsRecently, a phase II placebo-controlled trial of dronabinol reported dose-dependent reduction in the apnea-hypopnea index (AHI). A phase III trial exploring this link further is planned.SummaryCannabinoid use has variable effects in the treatment of OSA. Preliminary data are promising but insufficient regarding both efficacy and safety. Further research is needed to understand its role in management of OSA.